Good Thursday morning, everybody. As promised, we've got an early delivery of today's newsletter to make sure you have plenty of time to take action with today's trading alert on our newest Featured Stock. In fact, as a bonus for you regular newsletter readers, it's not even a Featured Stock at the site yet. We won't flip that switch until after the close today, which means you have a few hours of knowing something other investors don't. The usual caveats apply, of course. That is, understand that this is a speculative small cap, and as such, stops as well as limit orders are advised. Also, never invest more than you're willing to lose. On the other hand, the usual upsides apply too - catching the right stock at the right time is like catching lightning in a bottle. And in today's case, we think this is very much a right-time, right-place situation. This biopharma company has been laying low for a while, and if history repeats itself (which it usually does), something big news-wise has been brewing and is about to surface... the classic catalyst for small cap biotech stocks. Enough fanfare. As you already read from the headline, today's company is Relmada Therapeutics (RLMD), which is developing a quartet of pain treatments that could take the $13 billion pain-medicine prescription market by storm. Introducing Relmada Therapeutics Relmada Therapeutics is, in simplest terms, a developmental stage specialty pharmaceutical company that's not so much making new pain treatments, but making existing ones better. This low-risk (and low-cost) path to drug development is what makes the RLMD opportunity a standout. Opioids are narcotics are great at controlling pain... some of the time. But, they're problematic, and not just because some of these drugs are easy to abuse. Many of these drugs simply don't always do the job in the way they really need to do it in order to treat pain. The numbers confirm it: Of all chronic pain sufferers in the U.S., 51% of them say opioids give them little to no control over their pain. At the other end of the spectrum, only 23% of opioid users say their particular drug is "very effective" at controlling pain. It begs the question - what's the point? The issue at hand isn't a chemical formula's capability of killing pain, however. More often than not it's just the pace of delivery and the delivery mechanism itself that's less than ideal. This is where Relmada Therapeutics is aiming to make a difference - by developing the biotechnology to extend or pace the release of a drug once in the body as opposed to the bulk of a drug's physiological uptake being right when it's administered. Relmada Therapeutics has four unique drugs in the pipeline; to fully appreciate RLMD one has to at least get a grasp on what exactly is in the works. In no particular order... LevoCap ER (REL-1015) is an extended-release and abuse-resistant version of levorphanol BuTab (REL-1028) is to be the first traditional version of buprenorphine in an oral tablet MepiGel (REL-10021) is a topical/gel version of local anesthetic mepivacaine d-Methadone (REL-1017) is a new NMDA (N-methyl-D-aspartate) antagonist to treat neuropathic pain While three drugs in the pipeline are variations on a specific drug already on the market, all four could serve as suitable replacements for several pain-killers. The chart below tells you which, but better yet, the chart shows you what kind of revenue is on the radar for each. Why RLMD, and Why Now? Now, if you looked closely at the descriptions of the four drugs, you'll have thought it was interesting that three of them were simply reworks and reformatting of pain medications that are already on the market. This is a huge deal for investors. It's called a 505(b)(2) application, which in simplest terms means a drug-development company doesn't have to reinvent the wheel, so to speak, to bring a newly-formatted drug to the market by performing lengthy and expensive trials if that drug - the chemical or compound - has already been approved by the FDA. The only thing that needs to be proven in this case is that the controlled-release or extended-release formulations are still safe for users and perform as described. Almost needless to say, this is much faster and cheaper than the typical development of a new drug, which means Relmada Therapeutics may be much closer to getting a revenue-bearing product on the market than anyone realizes. The fact that LevoCap ER and BuTab are currently in phase 3 and phase 2/3 stages of development may be the biopharma industry's best-kept secret right now. Coming in a close second is the fact that d-Methadone and MepiGel are in phase 2 and phase 1/2 trials at this time. This means RLMD may have a product ready to go maybe even as soon as 2018, ready to tap into a (frankly) still underserved prescription-pain-killer market. Honestly though, we doubt you'll have to wait anywhere near that long to see the stock make bullish progress. Those of you who are biotech trading veterans will know the market doesn't just reward approved drugs. It rewards milestones reached en route to an approval. And, as the timetable below illustrates, there are a ton of milestones waiting to be met during the remainder of this year, all the way through 2017. This includes a possible uplisting of RLMD shares to the NASDAQ exchange... soon. No, we haven't heard or seen a great deal of pipeline updates from Relmada Therapeutics in a while, nor have we seen the stock do much of late. That's the point. There's no particular event or news coming that we're aware of. But, knowing what we do know about this company and also knowing what we know about how biopharma stocks trade in the real world, we think now would be a great time to put RLMD on your radar for one key reason... the stock is hovering around its all-time lows, but its volume on 14th (see the chart below) of this month suggests the possibility of something big brewing. The list of potential catalysts is plenty long, too. Bottom Line We love promising biotechs on pullbacks or new lows, as the risk/reward ratio is usually much better in those instances compared to buying them when they're running and everyone wants them. And, based on what you now know about RLMD, we think you'll agree there are going to be a lot of tangible reasons for the market to like the stock in the very near future. The kicker is the capitalization. For a company that's got a good shot at capturing a nice chunk of a $13 billion market, a market cap of only $45 million is a pittance. And, given how the company's got $22 million in the bank, the market is valuing the company's well-developed pipeline and IP at only about $23 million (the $15 million in debt you may see with some data sources isn't actually debt - it's a derivative liability that effectively goes away with an uplisting). That $23 million value is crazy for a pipeline of this caliber, which is why we don't think the market is going to keep overlooking RLMD for much longer. That's why we wanted to let you know about it as soon as possible... before something happened to let the proverbial cat out of the bag. You know the drill - if you're getting in, be smart about setting entry limits and then using reasonable stops afterwards. This is a really great story stock though, as the company brings very little risk to the table compared to its potential reward. We'd be surprised if RLMD wasn't trading at much higher levels in the near future, particularly if it achieves that NASDAQ uplisting.